Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...
Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Two-thirds of children classified BMI-overweight had normal fat estimated with waist-to-height ratio
Body mass index (BMI) was almost three times more likely to classify children as overweight than waist circumference-to-height ratio, according to a new study.
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
17h
Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback